DE2330902A1 - Energy-rich phosphate topical preparations - for therapeutic and prophylactic application to skin and eyes - Google Patents

Abstract

Pharmaceutical and skin-care preparations for external topical application to the skin or eyes of humans or animals for therapeutic or prophylactic purposes (e.g. powders, pastes, ointments, creams, gels, solutions, emulsions, milks, foams, sprays or drops) contain energy-rich phosphates (esp. adenosine triphosphate) as active ingredient. The preparations promote healing of skin damage of all kinds e.g. wounds, burns, ulcers, abscesses or fistulae. They are also effective against radiation damage of all kinds, and improve healing of transplants. They may be applied to the eyes for the treatment of traumatic and thermal damage of horny and connective tissue, damage due to radiation, acids or alkalis, and inflammations. The advantages of local topical application are that the energy-rich phosphate is able to act directly on the target organ, and that the energy-rich phosphate cannot give rise to undesired vascular side-effects because it is not absorbed into the cardiovascular system.

Description

Dr. Helmut Zander

Healing-promoting and preventive, for local need Use on the skin and in the eye for medicinal products or skin care products intended for humans and animals

The invention relates to a healing and preventive, Medicinal or skin care product intended for external topical use on the skin and in the eyes for humans and animals.

Energy-rich phosphates, primarily adenosine triphosphate (ATP), are known and biochemically defined, endogenous substances. So far, they have only been used as medicinal products enterally and parenterally Used in the types of application of tablets and injection solutions, mainly as a means of expanding blood vessels in coronary and peripheral circulatory disorders, also in myocardial infarction, in paroxysmal tachycardia, in liver disorders and myasthenia. In commercially available tablets, the ATP content is usually Io mg ATP per tablet commercially available ampoules, the ATP concentration is in the Order of magnitude from Io to 20 mg per milliliter. ATP tablets are ineffective, which, apart from the reasons that will be discussed further below, is essentially due to the fact that the substance On the way from the gastrointestinal tract to the target organs such as the heart or muscles, the liver has to pass and there so quickly and is completely broken down that it does not reach the target organ at all. ATP ampoules must be used intravascularly injected extremely slowly if dangerous circulatory collapse is to be avoided. With continuous intravascular infusion the dosage guidelines provide for a maximum dose of 60 mg ATP per hour for adults.

The intention to use energy-rich phosphates, primarily ATP, therapeutically, is based in the previous types of application on the property of the energy-rich phosphates, the blood vessels

509812/1051

_ 2. 233U902

to expand. The side effects result from the same property on the cycle. Even within the range of the standard dose, they lead to a reduction in blood pressure and thus a Slowing down of the flow, which has the intended therapeutic effect, namely increased blood flow through vasodilatation to achieve, back up again. Exceeding the standard dose does not result in better therapeutic effects, but rather causes devastating circulatory collapse with total circulatory arrest. The crucial points of view for the assessment the previous types of application are, however, in the following contexts, which have not been recognized by the professional world have been. The turnover of ATP in the body of an adult person is 3 kilograms (!) Per hour under resting conditions. The maximum permissible therapeutic dose for intravascular delivery is, as stated above, at 60 milligrams (1) per hour. 60 mg are related to 3 kg like 1: 50, ooo, i.e. it can be im At most, only a fifty-thousandth of the resting requirement is supplied to ATP, an amount that is a hopeless underdosing and is practically negligible. This numerical ratio, which has never been considered before, becomes even more hopeless, when the ATP requirement increases by a multiple of the resting metabolic rate under illness conditions such as a fever.

So it is no wonder that ATP supplements are not used in medical practice, primarily due to bad experiences could outgrow the role of an insignificant and useless therapeutic accessory, and that in the professional world that A solidified prejudice that high-energy phosphates cannot be used as drugs. ATP supplements are usually themselves not available in big city pharmacies, and some of the few pharmaceutical companies that even use this group of substances had accepted, had to stop sales for economic reasons.

The invention is based on the object of creating a new type of application for high-energy phosphates, which in more convincing Way overcomes the prejudice established in the professional world.

509812/1051

Energy-rich phosphates would not be useful as drugs, and the therapeutic potential of these substances could be used makes that has so far neither been recognized nor exploited.

This object is achieved according to the invention in that the energy-rich phosphates as different active ingredients of medicinal and Care products are applied externally and locally in Form of powders, pastes, ointments, creams, gels, solutions, shaking mixtures, Emulsions, milks, foams, sprays or drops. The therapeutic target organs for Energy-rich phosphates are the skin of the animal and human body and the eye. When manufacturing is a high-energy Phosphate, primarily ATP, as a different component according to the rules of dermatological and ophthalmological Galenics with an indifferent drug base, a so-called Vehicle processed into an externally applicable medicinal product or skin care product.

The advantage of this new type of application is that it is only with its help that the energy-rich phosphates can no longer be used Characteristic,. Carrier of immediately metabolizable biological To be energy, to be able to develop for therapeutic and prophylactic purposes. Because in this way and only in this way they let themselves be in In contrast to the previous types of application, no longer just in a hopeless underdosage of 1: 50,000, but in bring the required high doses to the target organs. The inevitable in the previous types of application canceling effects until there are no devastating side effects because the new type of application eliminates the need for transport by blood. The new type of application allows the agent to be applied in direct contact with the target organ. Also can be the energetic In contrast to the previous types of application, phosphates are no longer broken down prematurely in the liver because they are no longer have to pass through the liver on the way to the target organ. The new type of application secures the energy-rich phosphates in contrast to the previously ineffective types of application one

5 0 9 8 12/1051

widespread use as an effective and indispensable medicinal product Skin care products. Under their local high-dose influence The healing of skin wounds and other skin damage is much faster and less complicated. The scarring is more delicate and smoother. Healthy skin withstands harmful influences longer and more sustainably, Aging skin is better protected and nourished. The baby's skin is better cared for. Side effects or intolerance do not occur. Combinations with other, known skin active ingredients are possible. The economical production in large quantities do not cause any technical difficulties.

In detail, the progress made in practice lies in the new application of high-energy phosphates in a significant improvement in therapeutic and prophylactic Possibilities for poorly healing wounds of the skin of the human and animal body, especially in the case of skin damage Infants, otherwise with area wounds of any kind, with burns, scalds, chemical burns, frostbite, abrasions, in chronic lower leg ulcers, decubital ulcers, boils, abscesses and fistulas, radiation damage and in skin grafts to improve the healing of the graft, on the eye in traumatic and thermal corneal and conjunctival damage, in the case of chemical burns from acids and alkalis, in the event of radiation damage and inflammation and in corneal transplants.

Embodiments:

a) Adenosine 5'-triphosphate Na ₃ -SaIz 2o, ο

Lotio alba aquosa DRF ad loo, ο

D.S. : for external use

5 0 9 8 12/1051

b) Adenosine 5'-triphosphate Na ₃ -SaIz 15, ο
Aquae dest. ad loo, ο

D.S .: iso-osmotic solution for rinsing the ulcer

c) Adenosine 5'-triphosphate Na ₂ -Salz 80.0 Talc.venet. et Zinc.oxidat. ää ad Ιοο, ο

D.S .: Wound powder, sprinkle on several times a day

d) ATP-Na ₂ -SaIz Ιοο, ο PuIv. puriss.

D.S .: Wound powder to sprinkle on

e) ATP-Na ₀ 40% in cellulose glycolate propylene glycol jelly base

D.S. : Apply wound jelly, thick with the back of a knife

f) ATP-Na ₂ 4o, ο Ungt. emulsificans aquosum DAB 7 ad Ιοο, ο

. D.S .: 40% ATP wound cream

g) ATP-Na ₂ 25/6 in polyethylene glycol-cetyl alcohol base DS: 2556-strength ATP skin cream

h) ATP-Na, 3, o

Lanolin-Eucerin aa ad Ιοο, ο

D.S .: 3% ATP skin ointment

i) ATP-Na ₂ lo, o

Lanolin-Eucerin aa ad Ιοο, ο

D.S .: lo? & - ige ATP skin ointment

509812/1051

Claims (1)

Claims ti) Healing-promoting and preventive medicinal products or skin care products intended for external topical use on the skin and in the eyes for humans and animals, characterized in that it is used as a different active ingredient from, for example, powders, pastes, ointments, creams, gels, solutions, shaking mixtures, emulsions, milks, foams, sprays or drops contains high-energy phosphates.